Sign Out
Hypersensitivity to the active substance or to any of the excipients.
Hepatic impairment.
Phaeochromocytoma.
Concomitant use of entacapone and non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine).
Concomitant use of a selective MAO-A inhibitor plus a selective MAO-B inhibitor and entacapone (see Interactions).
A previous history of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis.
Continue with Google